• LKP, Principal Investigator/ Deputy Principal Investigator und Subinvestigator bei über 50 Phase I, II, III und IV klinischen Studien (Melanom, Merkelzellkarzinom, Plattenepithelkarzinom, Basalzellkarzinom, aktinische Keratosen, adenoid zystisches Karzinom sowie Psoriasis und Autoimmunekrankungen der Haut) seit 07/2013
• Sprachen: Griechisch (Muttersprache), Deutsch(C1), Englisch(C2)
• Grundkurs für Ästhetische Dermatologie/ Dermatologische Kosmetologie (Arbeitschaft Ästhetische Dermatologie und Kosmetologie-ADK), 07/2023
• GCP-Auffrischungskurs inkl. Update Kurs, 10/2022

Ressourcen stärken! Teamorientierte Führung im Krankenhaus, 02- 05/2022
• GCP-Auffrischungskurs inkl. Update Kurs, 02/2021
• Asklepion Academy 4. Tübinger Laserseminar, Tübingen, 01/2020
• GCP-Aufbaukurs, 06/2019
• Asklepion Academy 3. Tübinger Laserseminar, Tübingen, 01/2019
• GCP-Training Refresher, 12/2018
• Grundkurs für Ästhetische Dermatologie/ Dermatologische
Kosmetologie (Arbeitschaft Ästhetische Dermatologie und
Kosmetologie-ADK), 10/2018
• Grundkurs für Ästhetische Dermatologie/ Dermatologische
Kosmetologie (Arbeitschaft Ästhetische Dermatologie und Kosmetologie-ADK), 10/2017
• Asklepion Academy 1. Tübinger Laserseminar, Tübingen, 02/2017
• GCP-Training Refresher, 12/2016
• GCP II-Aufbaukurs (inkl. 2. und 3. AMG-Änderungsgesetzt), 01/2015
• GCP Basistraining AMG & MPG, 06/2013
• ILS-ERC (Immediate Life Support,European Resuscitation Council),
2008
• Windows Office (Msword, Powerpoint, Access), Internet, Linux,
Mednext (Oracle), Novell, SAP, Groupwise, Meona, Lauris, Centricity
Web, ChilliWeb, Citrix, SPSS, Endnote, RedCap

• Hellenic Society of Dermatology and Venereology
• European Academy of Dermatology and Venereology (EADV)
• Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
• Deutsche Krebsgesellschaft (DKG)
• European Association of Dermato Oncology (EADO)
• Deutsche Gesellschaft für Dermatochirurgie e.V.
• Landesärztekammer Baden-Württemberg, Deutschland
• Ärztekammer Athen, Griechenland

• Postgraduiertenprogramm „Bösartige Hauttumoren der Haut“,
  Krankenhaus „Andreas Syggros“, seit 02/2024
• U-Kurs, Nahtkurs, OSCE, Betreuung von PJ-Studenten auf Station/ Poliklinik, Wochenpraktika

• Dermatology Goes Pop(ular), 22-25 Juni 2023, Herakleion, Kreta
Stings, bites and diseases: Milben und Spinnen
• Kurs für die Frauenakademie der volkshochschule Stuttgart: Die Haut, unser größtes Sinnesorgan, 01/2023, Stuttgart
• Dermatoskopiekurs 2022, Tübingen
• Regierungspräsidium Tübingen 2022, Tübingen
• Nordschwarzwaldsymposium 2022, Karlsruhe
• Dermatoskopiekurs 2020, Tübingen
• Dermatoskopiekurs 2019, Tübingen
• Dermatoskopiekurs 2018, Tübingen
• Symposium Immunonkologie 2017, Stuttgart
• Dermatoskopiekurs 2017, Tübingen
• Symposium Immunonkologie 2016, Stuttgart
• Dermatoskopiekurs 2016, Tübingen
• Dermatoskopiekurs 2015, Tübingen

MK3475-587 (advanced tumors/ Principal Investigator and National
Coordinator), TED15297 (advanced solid tumors/ Principal Investigator),
ACT16845 (skin tumors/ Principal Investigator), Biontech BNT111-01
(Melanoma/ Principal Investigator), AstraZeneca Monette ATR (Melanoma/ Principal Investigator), BMS-CA224-098 (Melanoma/ Principal Investigator),
BMS-CA224-047 (Melanoma/ Principal Investigator), BMS-CA-027-002 (Melanoma/ Principal Investigator), BMS-CA209-76K (Melanoma/ Principal Investigator), BMS-CA209-067 (Melanoma/ Principal Investigator), BMSCA209-066 (Melanoma/ Principal Investigator), BMS-CA209-76K (Melanoma/ Principal Investigator), BMS-CA209-915 (Melanoma/ Principal Investigator),
BMS-CA209-8TT (Melanoma/ Principal Investigator), BMS-CA045-001 (Melanoma/ Principal Investigator), BMS-CA209-511 (Melanoma/ PrincipalInvestigator), MK3475-252 (Melanoma/ sub investigator), MK3475-PN002 (Melanoma/ sub-investigator), MK3475-V937-01 (Melanoma/ Principal Investigator), HUYA-HBI-8000-303 (Melanoma/ Principal Investigator),
BIOTECH-IO102-IO103-013 (Melanoma/ sub-investigator), Novartis
CLXH254C12201 (Melanoma/ Principal Investigator), PIVOT12-NEKTAR (Melanoma/ Principal Investigator), Philogen Pivotal intratumoral (Melanoma/ sub-investigator), Genentech-BELVA (Melanoma/ Principal Investigator),
Genentech-GO40558 (Melanoma/ Principal Investigator), RadioCoBrim (Melanoma/ Principal Investigator), AMGEN 20120139 (Melanoma/ Principal Investigator), NIVOMELA (Melanoma/ Deputy Principal Investigator),
MK3475-716 (Melanoma/ Deputy Principal-Investigator), SNEPS (Melanoma/ Principal Investigator), Roche Imbrella B (tumors/ Principal Investigator),
Roche Trilogy CO39262 (Melanoma/ Deputy Principal Investigator), MK3475- 054 (Melanoma/ Principal Investigator), BMS-CA-209-172 (Melanoma/ subinvestigator), Curevac-CV8102-008 (Melanoma and other tumors/ Principal Investigator and National Coordinator), CombiAD (Melanoma/ Principal Investigator), Combi-I (Melanoma/ Principal Investigator), IDERA Illuminate (Melanoma/ Principal Investigator), 4SC-Sensitize (Melanoma/ Principal Investigator), IOVANCE C-144-01 (Melanoma/ Principal Investigator),
ImmunoCobiVem2015 (Melanoma/ Principal Investigator), BRAIN-IP (Melanoma/ sub-investigator), BUMPER (Melanoma/ sub-investigator),
AMGEN20180115 (Melanoma/ Deputy Principal Investigator), Columbus (Melanoma/ Principal Investigator), 162A2301NEMO (Melanoma/ subinvestigator), IMMUNED (Melanoma/ sub investigator), AMGEN Masterkey 265 (Melanoma/ sub-investigator), AMGEN Masterkey 264 (Melanoma/ subinvestigator), ADMEC-O (cSCC/ sub-investigator), PHILOGEN L19IL2 i.v. (Melanoma/ sub-investigator), PACMEL (Melanoma/ sub-investigator), ORIGIMM-ORI-A-Ce001 (Acne vulgaris/ Deputy Principal Investigator),
DupiMorph (Morphea/ sub-investigator), AMGEN-CC-10004-PSOR 020- EMBRACE (Psoriasis/ Deputy Principal Investigator), PINPOINTCAIN457ADE15 (Psoriasis/ Deputy Principal Investigator), Leo-LP0160-1396- EMBRACE-1 (Psoriasis/ Deputy Principal Investigator), ARGNX-113-1904- ADDRESS (Pemphigus/ Deputy Principal Investigator), ARGNX-113-1905- ADDRESS + (Pemphigus/ Deputy Principal Investigator), Pelle-926-301 (BCC/ sub-investigator), R2810-ONC-1620 (BCC/ sub-investigator), Philogen Duncan (BCC, cSCC/ sub-investigator), KRT-232-103 (MCC/ Principal Investigator), MERKLIN-1 (MCC/ Principal Investigator), MERKLIN-2 (MCC/ Principal Investigator), INCMGA0012-201 (MCC/ sub-investigator), CerpassRPL-002-18 (cSCC/ Deputy Principal Investigator), IFX-1-P2.8 (cSCC/ Principal Investigator), Field Cancerization (cSCC/ sub-investigator), R2810- ONC-1788 (cSCC/ sub-investigator), MK3475-630 (cSCC/ sub investigator),
MK3475-629 (cSCC/ sub-investigator), Reg2810-ONC-1901 (cSCC/ Principal Investigator), ALICE (cSCC/ sub-investigator), Reg2810-ONC-1540 (cSCC/ sub-investigator), FLIMMA (Melanoma/ sub-investigator), NEO-VC-UKTRoche IIT (Melanoma/ sub-investigator), Phototox-GSK-Novartis IIT (Melanoma/ sub-investigator), LEO PICATO (actinic keratosis/ subinvestigator), EMR200066-007 (Melanoma/ sub-investigator), BOTTOM (Melanoma/ sub-investigator), BRF117277-Combi MB (Melanoma/ subinvestigator), CombiD_MEK115306 (Melanoma/ sub-investigator), CombiV_MEK116513 (Melanoma/ sub-investigator), DERMA-11482
(Melanoma/ sub-investigator), IMMOMEC (MCC/ sub-investigator), BRIM P (Melanoma/ sub-investigator), BRIM 8 (Melanoma/ sub-investigator), NO25026-E-BRIM3 (Melanoma/ sub-investigator), CoBRIM (Melanoma/ subinvestigator), Vemura-EAP MO25515 (Melanoma/ sub-investigator), VEM. BRAIN MO25743 (Melanoma/ sub-investigator), MIKIE (BCC/ subinvestigator), STEVIE (BCC/ sub-investigator), IMspire170 CO39722 (Melanoma/ sub investigator), NIS-NICO (Melanoma/ sub-investigator), Niels (BCC/ sub-investigator), Combi-r (Melanoma/ sub-investigator)

• Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid
Tumors. Part III: Transcranial Application, Immune Profile, Blood-Brain
Barrier, Neuroprotection, Neuromodulation and Neurostimulation.
Cell Physiol Biochem. 2026 Apr 10;60(2):175-188. doi: 10.33594/000000859
Theuer AE, Exner S, Thomas I, Lang F, Mullins JD, Warlick J, Strassmann G, Eigentler TK,
Walter GF
• Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid
Tumors. Part I: Animal Experiments, Clinical Application and
Immunological Abscopal Effect.
Cell Physiol Biochem. 2025 Nov 12;59(6):800-810. doi: 10.33594/000000828
Theuer AE, Thomas I, Lang F, Borkmann M, Mullins JD, Eigentler TK, Walter GF
• Nivolumab plus relatlimab vs nivolumab alone for the adjuvant
treatment of completely resected stage III–IV melanoma: Primary
results from RELATIVITY-098
Journal of Clinical Oncology Vol 43, Number 17_suppl
doi.org/10.1200/JCO.2025.43.17_suppl.LBA9500
Georgina V. Long, Paolo Antonio Ascierto, Jun Guo, Sunandana Chandra, Ahmad A. Tarhini,
Eva Muñoz Couselo, Michele Del Vecchio, Andreia Cristina De Melo, Helen Gogas, Reinhard
Dummer, Margaret K. Callahan, Dirk Schadendorf, Peter Koelblinger, Gaelle Quereux, Ioannis
Thomas, Bohang Chen, Alicia Mun Yen Cheong, Patrick Djidel, Sonia Dolfi, and Hussein A.
Tawbi
• Phase I study of intratumoral administration of CV8102 in patients with
advanced melanoma, squamous cell carcinoma of the skin, squamous
cell carcinoma of the head and neck, or adenoid cystic carcinoma
Journal for ImmunoTherapy of Cancer 2025;13:e009352. doi:10.1136/jitc-2024-009352
Thomas Eigentler, Ioannis Thomas, Igor Samoylenko, Michael Erdmann, Lucie Heinzerling,
Sebastian Ochsenreither, Jürgen Krauss, Arjun Oberoi, Caroline Robert, Celeste Lebbe, Juan
Martin-Liberal,
Lukas Koch, Erika Richtig, Patrick Terheyden, Carsten Weishaupt, Peter Mohr, Yulia
Semiletova, Casilda Llacer Perez, Peter Brossart, Franz Georg Bauernfeind, Michael Fluck,
Artem Poltoratskiy,
Marina Sekacheva, Ainara Soria, Beate Schmitt-Bormann, Marina Gonzalez, Jana Heß, Peter
Wengenmayer, Tobias Seibel, Sven D Koch, Gianluca Quintini, Paula Codó, Martin Falk,
Oliver Schönborn-Kellenberger, Ulrike Gnad-Vogt26
• EGFR expression is associated with relapse in a melanoma cohort
receiving adjuvant PD-1-based immunotherapy
J Am Acad Dermatol . 2023 Nov;89(5):1072-1074. doi: 10.1016/j.jaad.2023.06.057. Epub 2023
Jul 22 Teresa Amaral, Oltin Tiberiu Pop, Eftychia Chatziioannou, Tobias Sinnberg, Heike
Niessner, Jing Zhao, Sandra Stephanie Ring, Markus Joerger, Christopher Schroeder, Sorin
Armeanu-Ebinger, Antonio Cozzio, Ulrike Leiter, Ioannis Thomas, Wolfram Jochum, Claus
Garbe, Stephan Forchhammer, Mitchell Levesque, Joanna Mangana, Michael Hölzel, Reinhard
Dummer, Christian M Schürch, Andrea Forschner, Lukas Flatz
• Adjuvant immunotherapy with nivolumab versus observation in
completely resected Merkel cell carcinoma (ADMEC-O): disease-free
survival results from a randomised, open-label, phase 2 trial
The Lancet DOI: https://doi.org/10.1016/S0140-6736(23)00769-9
Jürgen C Becker, Selma Ugurel, Ulrike Leiter, Friedegund Meier, Ralf Gutzmer, Sebastian
Haferkamp, Lisa Zimmer, Elisabeth Livingstone, Thomas K Eigentler, Axel Hauschild, Felix
Kiecker, Jessica C Hassel, Peter Mohr, Michael Fluck, Ioannis Thomas, Marlene Garzarolli,
Imke Grimmelmann, Konstantin Drexler, Alexandra N Spillner, Sebastian Eckhardt, Dirk
Schadendorf, on behalf of DeCOG
• Features and Long-Term Outcomes of Stage IV Melanoma Patients
Achieving Complete Response Under Anti-PD-1-Based
Immunotherapy
Am J Clin Dermatol . 2023 May;24(3):453-467. doi: 10.1007/s40257-023-00775-7
Eftychia Chatziioannou, Ulrike Leiter, Ioannis Thomas, Ulrike Keim, Olivia Seeber, Andreas
Meiwes, Isabell Boessenecker, Stephanie Sanchez Gonzalez, Francisco Merraz Torres, Heike
Niessner, Tobias Sinnberg, Andrea Forschner, Lukas Flatz, Teresa Amaral
• Long-term outcomes in melanoma patients achieving a complete
response under immune checkpoint inhibition
IOTECH Immuno-oncology and technology DOI:https://doi.org/10.1016/j.iotech.2022.100194
E. Chatziioannou, U. Leiter-Stoppke, I. Thomas, U. Keim, A. Forschner, L. Flatz, T.M.S. Amaral
• 786 Intratumorally administered CV8102 in patients with advanced
solid tumors: preliminary results from ongoing expansion part in study
008
Journal for ImmunoTherapy of Cancer 10 (Suppl 2):A817-A817 DOI: 10.1136/jitc-2022-
SITC2022.0786
Conference Paper: SITC 37th Annual Meeting (SITC 2022)
Thomas Eigentler, Igor Samoylenko, Sebastian Ochsenreither, Erika Richtig, Ioannis Thomas,
Michael Erdmann, Celeste Lebbe, Juan José Soto-Castillo, Patrick Terheyden, Artem
Poltoratskiy, Marina Sekacheva, Yuliya Semiletova, Janina Henze, Beate Schmitt-Bormann,
Paula Codó, Martin Falk, Ulrike Gnad-Vogt
• 784 Immune profiling of patients with advanced melanoma
intratumorally treated with CV8102 as a single-agent or in combination
with anti-PD-1 antibodies – results of a phase I trial expansion
Journal for ImmunoTherapy of Cancer 10(Suppl 2):A815-A815 DOI: 10.1136/jitc-2022-
SITC2022.0784
Conference: SITC 37th Annual Meeting (SITC 2022)
Marina Gonzalez, Peter Wengenmayer, Igor Samoylenko, Sebastian Ochsenreither, Erika
Richtig, Ioannis Thomas, Michael Erdmann, Celeste Lebbe, Juan Martin-Liberal, Patrick
Terheyden, Artem Poltoratskiy, Marina Sekacheva, Yuliya Semiletova, Thomas Eigentler,
Beate Schmitt-Bormann, Dominik Vahrenhorst, Sarah-Katharina Kays, Tobias Seibel, Gianluca
Quintini, Birgit Scheel, Martin Falk, Ulrike Gnad-Vogt, Paula Codó
• Association between Immune-Related Adverse Events and Survival in
319 Stage IV Melanoma Patients Treated with PD-1-Based
Immunotherapy: An Approach Based on Clinical Chemistry
Cancers 2021, 13(23), 6141; https://doi.org/10.3390/cancers13236141
Lina María Serna Higuita, Teresa Amaral, Andrea Forschner, Ulrike Leiter, Lukas Flatz, Olivia
Seeber, Ioannis Thomas, Claus Garbe, Thomas Kurt Eigentler, Peter Martus
• Sequential targeted and immunotherapies in stage IV melanoma
Annals of Oncology, DOI:https://doi.org/10.1016/j.annonc.2021.08.1429
T.M.S. Amaral, J. Nolinski, H. Niessner, T. Sinnberg, O. Seeber, S. Sanchez, U. Keim, I.
Thomas, A. Meiwes, A. Koechel, A. Forschner, U. Leiter, L. Flatz, T. Eigentler, C. Garbe
• Primary resistance to checkpoint inhibition
Cancers, DOI: 10.3390/cancers12041027
Teresa Amaral, Olivia Seeber, Ioannis Thomas, Andreas Meiwes, Andrea Forschner, Ulrike
Leiter, Thomas Eigentler, Ulrike Keim, Claus Garbe
• Primary resistance to immune-checkpoint inhibitors in patients with
metastatic melanoma
Journal of Translational Medicine 2020, 18(Supp 1):16
Teresa Amaral, Zeinab Assi, Ulrike Keim, Andreas Meiwes, Ioannis Thomas, Julia Wilhelmi,
Thomas Eigentler, Claus Garbe, Olivia Seeber
• An open-label, single-arm, phase II trial of buparlisib in patients with
melanoma brain metastases not eligible for surgery or radiosurgery-the
BUMPER study
NeuroOncology Advances, https://doi.org/10.1093/noajnl/vdaa140
Teresa Amaral, Heike Niessner, Tobias Sinnberg, Ioannis Thomas, Andreas Meiwes, Claus
Garbe, Marlene Garzarolli, Ricarda Rauschenberg, Thomas Eigentler, Friedegund Meier
• Late recurrence of melanoma after 10 years – Is the course of the
disease different from early recurrences?
Journal of the European Academy of Dermatology and Venereology DOI: 10.1111/jdv.16106E
E Sarac, J Wilhelmi, I Thomas, U Leiter, U. Keim, T Eigentler, C Garbe, T Amaral
• Immune-related adverse events associated with checkpoint inhibitors
therapy in a real world setting
Journal: Journal of Translational Medicine, 2019, 17(Supp 1): 14
Teresa Amaral, Thomas Eigentler, Paloma Caballero, Ioanna Tampouri, Diana Lomberg,
Zeinab Assi, Ioannis Thomas, Ansgar Koechel, Alisa Mueller, Lukas Kofler, Ulrike Leiter,
Andrea Forschner, Claus Garbe
• Cutaneous, gastrointestinal, hepatic, endocrine and renal side effects
of anti-PD-1 therapy
European Journal Of Cancer 2016, DOI: 10.1016/j.ejca.2016.02.025
Hofmann L, Forschner A, Loquai C, Goldinger S, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer
R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M,
Wahl R, Dietrich U, Garbe C, Kirchberger M, Eigentler T, Berking C, Gesierich A, Krackhardt
AM, Schadendorf D, Schuler G, Dummer R, Heinzerling L
• Neurological, respiratory, musculoskeletal, cardiac and ocular side
effects of anti-PD-1 therapy
European Journal Of Cancer 2016, DOI: 10.1016/j.ejca.2016.02.024
Zimmer L, Goldinger S, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen M, Gutzmer R,
Utikal J, Göppner D, Hassel J, Meier F, Tietze J, Forschner A, Weishaupt C, Leverkus M, Wahl
R, Dietrich U, Garbe C, Kirchberger M, Eigentler T, Berking C, Gesierich A, Krackhardt A,
Schadendorf D, Schuler G, Dummer R, Heinzerling L

• Number of IL-2 doses and clinical outcomes of tumor-infiltrating
lymphocyte (TIL) cell therapy: A post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma Annals of Oncology (2022) 16 (suppl_1): 100101-100101. 10.1016/iotech/iotech100101 ESMO IO 2022 |
Jessica C. Hassel, Amod Sarnaik, Jason Chesney, Theresa Medina, Omid Hamid, Sajeve Thomas, Martin Wermke, Evidio Domingo-Musibay, John M. Kirkwood, James Larkin, Jeffrey Weber, Ana Maria Arance Fernandez, Juan Francisco Rodríguez Moreno, Ioannis Thomas, Alfonso Berrocal Jaime, Pippa Corrie, Viktoria Gontcharova, Xiao Wu, Wen Shi, Harriet Kluger
• Adjuvant immunotherapy with nivolumab vs. observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival results from ADMEC-O, a randomized, open-label phase 2 trial
September 2022 Annals of Oncology 33:S903 DOI: 10.1016/j.annonc.2022.07.913 ESMO 2022
J.C. Becker, S. Ugurel, U. Leiter, F. Meier, R. Gutzmer, S. Haferkamp, L. Zimmer, E. Livingstone, T. Eigentler, A. Hauschild, F. Kieker, J.C. Hassel, Pe. Mohr, M. Fluck, I. Thomas, M. Garzarolli, I. Grimmelmann, K. Drexler, S.Eckhardt, D. Schadendorf on behalf of the DeCOG
• Unerwünschte kardiale Nebenwirkungen unter BRAF- und MEKInhibitor-Therapie 32. Deutscher Hautkrebskongress 2022 – Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
I. Bössenecker, O. Seeber, A. Meiwes, S. Sanchez Gonzalez, H. Niessner, T. Sinnberg, I. Thomas, A. Forschner, U. Leiter-Stöppke, C. Garbe, L. Flatz, T. Eigentler, T. Amaral
• Which method should be used to evaluate body composition as a predictive factor for immunotherapy response in melanoma patients? A one center survey 32. Deutscher Hautkrebskongress 2022 – Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
S. Sanchez Gonzalez, L. Serna-Higuita, S. Afat, I. Thomas, O. Seeber, I. Bössenecker, U. Leiter-Stöppke, C. Garbe, L. Flatz, T. Eigentler, T. Amaral
• Sarkoidose unter Immun-Checkpoint-Inhibitoren 28. Deutscher Hautkrebskongress 2018 – Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
Tampouri I., Lomberg D., Assi Z., Thomas I., Koechel A., Amaral T., Silber T., Müller A., Kofler L., Forschner A., Garbe C., Eigentler T.
• Myasthenia gravis unter Systemtherapie mit der kombinierten
Immuntherapie Ipilimumab und Nivolumab 28. Deutscher Hautkrebskongress 2018 – Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
Toni Silber, Irina Gepfner-Tuma, Alisa Müller, Ioannis Thomas, Katrin Schweinzer, Lukas Kofler, Diana Lomberg, Ansgar Koechel, Ioanna Tampouri, Thomas Eigentler, Claus Garbe, Ghazaleh Tabatabai, Andrea Forschner
• Zunehmender Schwindel, Übelkeit und Ataxie unter einer kombinierten Immuntherapie bei Malignem Melanom St. IV 28. Deutscher Hautkrebskongress 2018 – Arbeitsgemeinschaft Dermatologische Onkologie (ADO)
Alisa Müller, Irina Gepfner- Tuma, Teresa Amaral, Gazaleh Tabatabai, Lukas Kofler, Toni Silber, Katrin Schweinzer, Ioannis Thomas, Gwendolyn Glatthaar, Diana Lomberg, Ioanna Tampouri, Thomas Eigentler, Claus Garbe, Andrea Forschner
• Galvanotherapy effectively necrotizes cutaneous melanoma
metastases and has the potential as a tumor antigen releasing therapy 13th congress of the EADO 2017
Ioanna Tampouri, Maximilian Gassenmaier, Heike Niessner, Tobias Sinnberg, Ioannis Thomas, Claus Garbe
• Drug reaction with eosinophilia and systemic symptoms (DRESS) nach Einnahme von Vemurafenib und Cobimetinib bei metastasiertem Melanom 27. Deutscher Kongress ADO 2017
Tampouri I., Thomas I, Koechel A, Meiwes A, Wilhelmi J, Lomberg D, Pierchalla K, Garbe C, Eigentler T.
• Basal cell carcinoma: two cases of vismodegib therapy in extended advanced BCC 13th EADV Spring symposium 2016
Tampouri I, Eigentler T, Weide B, Thomas I, Lomberg D, Spänkuch I, Garbe C, Leiter U